PL3493812T3 - Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej - Google Patents

Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej

Info

Publication number
PL3493812T3
PL3493812T3 PL17748613.1T PL17748613T PL3493812T3 PL 3493812 T3 PL3493812 T3 PL 3493812T3 PL 17748613 T PL17748613 T PL 17748613T PL 3493812 T3 PL3493812 T3 PL 3493812T3
Authority
PL
Poland
Prior art keywords
myelonel
imetelstat
venetoclax
leukemia
acute
Prior art date
Application number
PL17748613.1T
Other languages
English (en)
Inventor
Fei Huang
Joshua J. RUSBULDT
Aleksandra RIZO
Original Assignee
Geron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corporation filed Critical Geron Corporation
Publication of PL3493812T3 publication Critical patent/PL3493812T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Glass Compositions (AREA)
  • Photoreceptors In Electrophotography (AREA)
PL17748613.1T 2016-08-02 2017-07-28 Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej PL3493812T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662370018P 2016-08-02 2016-08-02
EP16197293.0A EP3318276A1 (en) 2016-11-04 2016-11-04 Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
US201662422738P 2016-11-16 2016-11-16
PCT/US2017/044348 WO2018026646A1 (en) 2016-08-02 2017-07-28 Combination treatment for hematological cancers

Publications (1)

Publication Number Publication Date
PL3493812T3 true PL3493812T3 (pl) 2023-05-08

Family

ID=57226888

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17748613.1T PL3493812T3 (pl) 2016-08-02 2017-07-28 Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej

Country Status (28)

Country Link
US (2) US11278561B2 (pl)
EP (3) EP3318276A1 (pl)
JP (3) JP7016856B2 (pl)
KR (3) KR102515378B1 (pl)
CN (2) CN116327954A (pl)
AU (2) AU2017305950B2 (pl)
CA (2) CA3217021A1 (pl)
CL (1) CL2019000228A1 (pl)
DK (1) DK3493812T3 (pl)
ES (1) ES2941462T3 (pl)
FI (1) FI3493812T3 (pl)
HR (1) HRP20230300T1 (pl)
HU (1) HUE061471T2 (pl)
IL (2) IL264451B2 (pl)
LT (1) LT3493812T (pl)
MA (1) MA45845B1 (pl)
MD (1) MD3493812T2 (pl)
MX (2) MX395085B (pl)
NZ (1) NZ750191A (pl)
PL (1) PL3493812T3 (pl)
PT (1) PT3493812T (pl)
RS (1) RS64074B1 (pl)
SG (1) SG11201900883UA (pl)
SI (1) SI3493812T1 (pl)
SM (1) SMT202300108T1 (pl)
UA (1) UA124935C2 (pl)
WO (1) WO2018026646A1 (pl)
ZA (1) ZA201900939B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
EP3658156B1 (en) 2017-07-28 2026-03-25 Geron Corporation Telomerase inhibitor for use in treating a myelodysplastic syndrome
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
CN112770783B (zh) * 2018-07-31 2025-02-25 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
CN113631719A (zh) 2018-11-29 2021-11-09 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法
JP7585231B2 (ja) * 2019-04-29 2024-11-18 イミュノジェン， インコーポレイテッド 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ
CA3181682A1 (en) * 2020-07-17 2022-01-20 Anil Kapur Subcutaneous telomerase inhibitor compositions and methods for using same
JP2024504367A (ja) * 2021-01-22 2024-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療及び改善するための方法
CA3175913A1 (en) * 2021-07-16 2023-01-16 Celator Pharmaceuticals, Inc. Liposomal formulations of bcl inhibitors
EP4463151A4 (en) 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy
CN114949230B (zh) * 2022-06-13 2024-12-06 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN118593709B (zh) * 2024-05-28 2025-05-23 湖南大学 Fasn抑制剂的新用途、化合物、化合物的新用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5776679A (en) 1994-07-07 1998-07-07 Geron Corporation Assays for the DNA component of human telomerase
HK1049339B (en) 1999-09-10 2008-06-27 Geron Corporation Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use
DK3342425T3 (da) 2003-09-09 2020-03-16 Geron Corp Modificerede oligonukleotider til inhibering af telomerase
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
WO2006124904A2 (en) 2005-05-16 2006-11-23 Geron Corporation Cancer treatment by combined inhibition of telomerase and hsp90 activities
EP4600359A2 (en) 2006-10-30 2025-08-13 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
ES2407957T3 (es) 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
EP3719139B1 (en) 2008-10-17 2022-11-30 Geron Corporation Method for identification of sensitivity of a patient to telomerase inhibition therapy
US8772264B2 (en) * 2009-08-04 2014-07-08 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
SG11201503459SA (en) * 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
LT2925889T (lt) 2012-11-30 2018-12-27 Geron Corporation Diagnostiniai žymenys, skirti ląstelių prolifreracijos sutrikimų gydymui telomerazės inhibitoriais
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
PT3456333T (pt) 2012-12-07 2020-06-01 Geron Corp Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
SG11201507106PA (en) * 2013-03-14 2015-10-29 Onyx Therapeutics Inc Dipeptide and tripeptide epoxy ketone protease inhibitors
WO2014160071A1 (en) * 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
US11123359B2 (en) 2013-11-06 2021-09-21 Mayo Foundation For Medical Education And Research Methods and materials for treating hematological malignancies
WO2015191568A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US9635050B2 (en) 2014-07-23 2017-04-25 Cisco Technology, Inc. Distributed supervised architecture for traffic segregation under attack
WO2016046346A1 (en) 2014-09-24 2016-03-31 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Monolayer of pbmcs or bone-marrow cells and uses thereof
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
EP3658156B1 (en) 2017-07-28 2026-03-25 Geron Corporation Telomerase inhibitor for use in treating a myelodysplastic syndrome

Also Published As

Publication number Publication date
ZA201900939B (en) 2023-04-26
KR102515378B1 (ko) 2023-03-29
KR102854375B1 (ko) 2025-09-04
IL264451A (en) 2019-02-28
CN109641002A (zh) 2019-04-16
ES2941462T3 (es) 2023-05-23
AU2023229592A1 (en) 2023-10-05
EP3493812B1 (en) 2023-01-04
HRP20230300T1 (hr) 2023-05-12
JP2019523277A (ja) 2019-08-22
SG11201900883UA (en) 2019-02-27
UA124935C2 (uk) 2021-12-15
KR20190049708A (ko) 2019-05-09
MA45845B1 (fr) 2025-08-29
MD3493812T2 (ro) 2023-05-31
AU2017305950B2 (en) 2023-06-22
SMT202300108T1 (it) 2023-05-12
IL264451B2 (en) 2024-01-01
FI3493812T3 (fi) 2023-04-14
AU2017305950A1 (en) 2019-02-21
MA45845A (fr) 2019-06-12
IL264451B1 (en) 2023-09-01
WO2018026646A1 (en) 2018-02-08
PT3493812T (pt) 2023-03-30
JP7016856B2 (ja) 2022-02-07
CL2019000228A1 (es) 2019-05-17
LT3493812T (lt) 2023-04-11
NZ750191A (en) 2023-03-31
HUE061471T2 (hu) 2023-07-28
DK3493812T3 (da) 2023-04-11
US20180036336A1 (en) 2018-02-08
EP3493812A1 (en) 2019-06-12
CA3032118A1 (en) 2018-02-08
MX2022010466A (es) 2022-09-19
KR20230047206A (ko) 2023-04-06
BR112019002025A2 (pt) 2019-05-14
EP3318276A1 (en) 2018-05-09
CN109641002B (zh) 2022-10-18
US11278561B2 (en) 2022-03-22
KR20250134002A (ko) 2025-09-09
CA3217021A1 (en) 2018-02-08
SI3493812T1 (sl) 2023-05-31
JP2022145948A (ja) 2022-10-04
MX2019001315A (es) 2019-07-01
EP4218768A1 (en) 2023-08-02
US20220168333A1 (en) 2022-06-02
CA3032118C (en) 2023-12-12
CN116327954A (zh) 2023-06-27
JP2024166290A (ja) 2024-11-28
RS64074B1 (sr) 2023-04-28
MX395085B (es) 2025-03-24
IL305332A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
PL3265053T3 (pl) Sposoby leczenia skóry
IL253162A0 (en) Compositions and methods for treatment and detection of cancers
EP3526222A4 (en) TYK2 INHIBITORS AND THEIR USES
EP3528816A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP3463464A4 (en) ASSOCIATION TREATMENT
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
IL263680A (en) Combination therapies
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
FIC20260013I1 (fi) ikodekinsuliini ja semaglutidi
PT3548033T (pt) Compostos e respectivos métodos de utilização
EP3564335A4 (en) SURFACE TREATMENT AGENT
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
HUE063044T2 (hu) Anti-CD38 ellenanyagok akut limfoblasztos leukémia kezelésére
DK3778595T3 (da) Pancreatitisbehandling
IL258259B (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
DK3493812T3 (da) Kombinationer af imetelstat og venetoclax til behandling af akut myeloid leukæmi
IL262926A (en) Mic-1 compounds and use thereof
IL248555A0 (en) Methods for characterizing and treating acute myeloid leukemia
PL3672948T3 (pl) Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
EP3597225A4 (en) TREATMENT PROCESS
IL254825A0 (en) Methods of treatment with taselisib